Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 20, 2025
Data Byte

FDA’s new and supplemental approvals in February

Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Aug 23, 2024
Regulation

Insulin production could move offshore

Did CMS negotiate too big of a discount? 
BioCentury | Nov 22, 2023
Politics, Policy & Law

GOP asks CBO to address concerns about the IRA

CBO asked to consider impacts on post-approval indications, delays in launching smaller indications, effects on generic, biosimilar competition 
BioCentury | Oct 3, 2023
Politics, Policy & Law

Novo Nordisk contends CMS violated IRA by lumping products

Lawsuit follows denied request for a preliminary injunction in Chambers of Commerce case
BioCentury | Sep 28, 2023
Politics, Policy & Law

Four drug companies signal plans to start IRA process

A fifth company, Novo Nordisk ‘exploring options’
BioCentury | Aug 30, 2023
Politics, Policy & Law

IRA drug list underscores challenges for industry

Selections underline difficulty in predicting how Inflation Reduction Act will be implemented
BioCentury | Jun 24, 2022
Politics, Policy & Law

Bribery allegations at Indian drug regulator

Central Bureau of Investigation alleges widespread corruption
BioCentury | Mar 1, 2022
Deals

Viatris biosimilars deal gives lift to Biocon’s global aspirations

$3.3B deal with Mylan-Upjohn offshoot gives Indian biotech leader pipeline of 20 biosimilars and over $1B in revenue
Items per page:
1 - 10 of 163